𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Immunotherapy with dendritic cells for prostate cancer

✍ Scribed by Anna-Katharina Thomas-Kaskel; Cornelius F. Waller; Wolfgang Schultze-Seemann; Hendrik Veelken

Publisher
John Wiley and Sons
Year
2007
Tongue
French
Weight
152 KB
Volume
121
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Radical prostatectomy for prostate cancer is followed by PSA recurrence in up to 40% of patients. One third of patients with biochemical relapse progress to uncurable metastatic disease. Therefore, alternative treatment modalities are needed both in the situation of PSA recurrence and in hormone‐refractory disease. Dendritic cells (DC) are the most powerful antigen‐presenting cells, able to prime naïve T‐cells and to break peripheral tolerance and thus induce tumor immune responses. More than 400 prostate cancer patients have been treated with DC‐based immunotherapy to date, and immune responses have been reported in two‐thirds of these, resulting in clinical responses in almost half of the patients treated. Most responses, however, were modest and transient. Therefore, mechanisms of treatment failure and possibilities to improve vaccination efficacy are being discussed. © 2007 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Lentivirally transduced dendritic cells
Lentivirally transduced dendritic cells as a tool for cancer immunotherapy
✍ Karine Breckpot; Melissa Dullaers; Aude Bonehill; Sonja Van Meirvenne; Carlo Hei 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 348 KB

## Abstract ## Background Dendritic cells (DC) are the professional antigen‐presenting cells of the immune system, fully equipped to prime naive T cells and thus essential components for cancer immunotherapy. ## Methods We tested the influence of several elements (cPPT, trip, WPRE, SIN) on the t

Monitoring of circulating angiogenic fac
Monitoring of circulating angiogenic factors in dendritic cell–based cancer immunotherapy
✍ Christine Brostjan; Anita Bayer; Anna Zommer; Alexander Gornikiewicz; Sebastian 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB

## Abstract ## BACKGROUND A promising treatment approach for patients with malignant disease that recently has found its way into clinical trials is based on vaccination with autologous dendritic cells loaded with tumor antigens. However, adequate assays for monitoring clinical and immunologic res

Depicting adoptive immunotherapy for pro
Depicting adoptive immunotherapy for prostate cancer in an animal model with magnetic resonance imaging
✍ Reinhard Meier; Daniel Golovko; Sidhartha Tavri; Tobias D. Henning; Christiane K 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 466 KB

## Abstract Genetically modified natural killer (NK) cells that recognize tumor‐associated surface antigens have recently shown promise as a novel approach for cancer immunotherapy. To determine NK cell therapy response early, a real‐time, noninvasive method to quantify NK cell homing to the tumor

Follow-up evaluation of prostate cancer
Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides
✍ Tjoa, B.A.; Erickson, S.J.; Bowes, V.A.; Ragde, H.; Kenny, G.M.; Cobb, O.E.; Ire 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 211 KB 👁 2 views

## BACKGROUND. We recently conducted a phase I clinical trial administering autologous dendritic cells pulsed with prostate-specific membrane antigen (PSMA) peptides to advanced prostate cancer patients. Participants were divided into 5 groups receiving 4 or 5 infusions of peptides alone (PSM-P1 o